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Abstract
VE-cadherin plays a central role in controlling endothelial barrier function, which is transiently disrupted by proinflamma-
tory cytokines such as tumor necrosis factor (TNFα). Here we show that human endothelial cells compensate VE-cadherin 
degradation in response to TNFα by inducing VE-cadherin de novo synthesis. This compensation increases adherens junc-
tion turnover but maintains surface VE-cadherin levels constant. NF-κB inhibition strongly reduced VE-cadherin expres-
sion and provoked endothelial barrier collapse. Bacterial lipopolysaccharide and TNFα upregulated the transcription factor 
ETS1, in vivo and in vitro, in an NF-κB dependent manner. ETS1 gene silencing specifically reduced VE-cadherin protein 
expression in response to TNFα and exacerbated TNFα-induced barrier disruption. We propose that TNFα induces not only 
the expression of genes involved in increasing permeability to small molecules and immune cells, but also a homeostatic 
transcriptional program in which NF-κB- and ETS1-regulated VE-cadherin expression prevents the irreversible damage of 
endothelial barriers.
Keywords Endothelial barrier function · Permeability · VE-cadherin · NF-κB · ETS1 · LPS · Resolution of inflammation · 
Adherens junctions · Degradation
Introduction
A major effect of long-term inflammatory stimulation is the 
progressive and transient disruption of endothelial barrier 
integrity, which underlies the development of many proin-
flammatory diseases. Inflammatory cytokines such as TNFα, 
interferon (IFN)-γ and interleukin (IL)-1β induce actin-
dependent morphological remodeling and a transcriptional 
program to express proteins that increase vascular leakiness 
to immune cells and small molecules through mechanisms 
that are not fully understood [1, 2].
Vascular endothelial (VE)-cadherin-dependent adherens 
junctions (AJs) are the main regulators of endothelial barrier 
properties in many vascular beds [3, 4]. VE-cadherin is the 
transmembrane partner of cytoplasmic catenins, which sta-
bilize the junctional complex at the cell border and connect 
AJs to the underlying actin cytoskeleton. Surface VE-cad-
herin not only regulates permeability, but also promotes cell 
survival, controls gene transcription, cytoskeleton remod-
eling and collective endothelial cell migration [3, 5–7]. This 
wide range of functions suggests that the expression and 
localization of VE-cadherin must be finely tuned even in the 
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context in which barrier function is transiently compromised 
during the inflammatory response. Inflammatory cytokines 
and other inflammatory mediators activate the src family-
dependent tyrosine phosphorylation of the cytoplasmic tail 
of VE-cadherin, which uncouples p120-catenin from VE-
cadherin, causing the disruption of AJs and the subsequent 
internalization of VE-cadherin [2, 8, 9]. However, the effects 
of cytokine stimulation on VE-cadherin expression and 
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stability have not yet been clarified. It has been shown that 
at least TNFα and the bacterial endotoxin lipopolysaccharide 
(LPS) can induce VE-cadherin shedding or intracellular deg-
radation, although this induction does not necessarily reduce 
cellular VE-cadherin levels [10]. Increased VE-cadherin 
degradation has been observed by simultaneous stimulation 
of vascular endothelial cells with more than two inflam-
matory cytokines or by a combination of certain cytokines 
and immune cells [11]. In contrast, several reports indicate 
that single cytokine stimulation causes barrier dysfunction 
in many endothelial beds without significantly decreasing 
VE-cadherin expression levels [8, 9, 12, 13].
Taking TNFα as a paradigm of inflammatory stimulus 
that progressively disrupts cellular barriers, and combining 
biochemical surface labeling and high-resolution micros-
copy, we have comprehensively analyzed the effect of this 
cytokine on surface VE-cadherin expression and dynamics 
in primary human endothelial cells. We show that long-term 
stimulation with TNFα increases endothelial permeability 
and reduces surface VE-cadherin half-life but not total VE-
cadherin levels. TNFα induces the compensatory expres-
sion of a VE-cadherin intracellular pool through NF-κB-
dependent regulation of the transcription factor ETS1, which 
compensates VE-cadherin degradation. Indeed, inhibiting 
NF-κB abrogates VE-cadherin and ETS1 expression and 
causes the collapse of the endothelial barrier, whereas ETS1 
gene silencing specifically regulates VE-cadherin expres-
sion, but not other TNFα-regulated genes, and exacerbates 
TNFα-mediated barrier dysfunction. Thus, our results 
suggest that endothelial cells implement a transcriptional 
program, which involves de novo expression of ETS1 and 
VE-cadherin, to preserve barrier integrity in response to 
inflammatory cytokines.
Results
De novo VE‑cadherin expression compensates 
for reduction of surface VE‑cadherin protein half‑life 
in response to TNFα
TNFα induces a progressive increase of permeability in 
many cellular barriers [2]. In human umbilical vein endothe-
lial cells (HUVECs), long-term exposure to TNFα reduces 
TEER from 25 to 40% of initial values (Fig. 1a) [1], remod-
els the endothelial cytoskeleton (Fig. 1b), alters the crosstalk 
between VE-cadherin and other cell–cell junction proteins 
and reduces cell density (Fig. S1A) [1, 13, 14]. This causes 
VE-cadherin reorganization, decreasing reticular AJs and 
increasing discontinuous AJs, orthogonal to cell borders and 
aligned with stress fibers (Fig. 1b) [1, 13]. We set out to 
quantify the effect of TNFα on surface VE-cadherin half-
life by performing pulse and chase experiments of endog-
enous surface VE-cadherin labeled with sulfo-NHS-biotin. 
HUVECs were stimulated or not with TNFα for 24 h and 
their surface proteins were biotinylated for 30 min (Fig. 1c, 
biotin pulse, time 0 post-biotinylation). Biotin-labeled 
cells were then incubated at 37 °C and lysed at different 
times (Fig. 1c, chase). Biotinylated surface proteins were 
isolated by pull-down assay with NeutrAvidin agarose [15] 
and endogenous VE-cadherin protein levels in the lysates 
(Fig. 1c, total) were compared with those in the pull-down 
fraction (Fig. 1c, surface). As a control, VE-cadherin was 
not detected in the pull-down fraction from non-biotinylated 
cells (Fig. 1c). Biotinylated VE-cadherin levels in HUVECs 
treated with TNFα for 24 h (Fig. 1c) and 8 h (Fig. 1d) 
decreased faster than in unstimulated HUVECs. From these 
experiments, we calculated that surface VE-cadherin protein 
half-life decreased from approximately 6 h in unstimulated 
cells to 2 h and 3 h in cells previously stimulated with TNFα 
for 24 h and 8 h, respectively. Treatment with lactacystin or 
MG132 indicated that proteasome is involved in acceler-
ated biotinylated-VE-cadherin protein decrease in response 
to TNFα (Fig. S1B). As a complementary approach, we 
labeled junctional VE-cadherin with a specific antibody 
that does not alter AJ dynamics [16]. Confocal microscopy 
analysis showed that VE-cadherin labeling decreased faster 
in cells pretreated with TNFα for 24 h than in untreated cells 
Fig. 1  TNFα induces endothelial barrier remodeling and decreases 
surface VE-cadherin half-life. a HUVECs were plated at confluence 
for 48 h in ECIS arrays pre-coated with fibronectin, then starved for 
12 h, stimulated or not with 10 ng/ml TNFα and TEER measured by 
ECIS. b HUVECs were cultured at confluence for 48 h on coverslips 
pre-coated with fibronectin, starved for 12 h and then stimulated or 
not with 10 ng/ml TNFα for 24 h. Cells were fixed and stained to ana-
lyze the distribution of VE-cadherin and F-actin. Scale bar, 20  μm. 
c, d Pulse and chase experiment of surface VE-cadherin. HUVECs 
were cultured at confluence for at least 48 h on dishes pre-coated with 
fibronectin, starved for 12 h and then stimulated or not with 10 ng/ml 
TNFα for 24 h (c) or for 8 h (d). Surface proteins were labeled with 
sulfo-NHS-biotin (biotin pulse), cells were incubated at 37 oC for the 
indicated times and lysed (chase). Surface-biotinylated proteins were 
isolated by pull-down assay with NeutrAvidin-agarose. Surface VE-
cadherin levels were detected with a specific antibody from the pull-
down fraction and compared with total VE-cadherin levels from the 
lysate. Immunoblots of ERK are shown as loading controls. Graphs 
show the mean + SEM from three independent experiments. Discon-
tinuous lines mark surface VE-cadherin half-life for each condition. 
The t test analyzed differences between surface VE-cadherin levels 
in unstimulated and TNFα-stimulated cells at the indicated times 
*p < 0.05; **p < 0.01. e HUVECs were cultured at confluence for at 
least 48 h on coverslips pre-coated with fibronectin, starved for 12 h 
and then stimulated or not with 10 ng/ml TNFα for 24 h. Cells were 
then incubated in the cold with mouse anti-VE-cadherin labeling anti-
body (surface), as described [16]. HUVECs were then incubated at 
37  oC for the indicated times, fixed, permeabilized and stained with 
a rabbit anti-VE-cadherin antibody (total). Scale bar, 20    μm. The 
right-hand graph shows the ratio between the staining intensities 
of  total and surface-labeled VE-cadherin antibody. Graph shows the 
mean + SEM from four independent experiments. *p < 0.05. See also 
Fig. S1
◂
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(Fig. 1e). Together, pulse and chase and antibody-mediated 
labeling experiments indicate that TNFα decreases the half-
life of surface VE-cadherin located at junctional domains. 
Dose–response assays showed that TNFα caused a 15% 
decrease in cell density at 10 ng/ml TNFα, the cytokine 
concentration used for the pulse-chase experiments (Fig. 
S1A). This decrease may contribute to surface VE-cadherin 
instability, but had no effect on PECAM-1 surface levels and 
stability, suggesting that this concentration of TNFα does 
not induce a general effect on the half-life of junctional pro-
tein complexes (Fig. S1C).
Although surface VE-cadherin stability, analyzed by 
pulse and chase experiments, decreased in cells exposed to 
TNFα, total surface VE-cadherin levels, detected immedi-
ately after the pulse with sulfo-NHS-biotin, remained unal-
tered over the time course of TNFα stimulation (pulse in 
Fig. 1c, d, time 0 post-biotinylation, and Fig. 2a). Moreover, 
when lysates were analyzed, a transient increase in total VE-
cadherin was detected between 4 and 24 h after TNFα stimu-
lation (Fig. 2a), suggesting that endothelial cells activate 
mechanisms to express intracellular VE-cadherin molecules 
that compensate for surface VE-cadherin degradation, yield-
ing constant surface VE-cadherin levels. Confocal analysis 
of the VE-cadherin distribution revealed a transient accumu-
lation of this protein in an intracellular compartment upon 
TNFα exposure (Fig. 2b). This intracellular pool colocalized 
with GM130, a Golgi marker (Fig. 2b, enlarged area), which 
is compatible with accumulation in the Golgi apparatus of 
newly synthesized VE-cadherin in response to TNFα. The 
increase in VE-cadherin was also observed in the HUVEC-
derived cell line, EA.hy926 and, to a lesser extent, in human 
dermal microvascular endothelial cells (HDMVECs) stimu-
lated with TNFα (Fig. 2c). In contrast, other components of 
AJs, such as catenins, and other vascular cadherins, such as 
N-cadherin [4, 17], did not change expression in response 
to TNFα (Fig. S2).
Intracellular VE‑cadherin partially compensates 
for surface VE‑cadherin decrease during acute 
barrier disruption
In an inflammatory context, endothelial beds are subjected to 
acute disruption of their integrity by mechanical, thrombotic, 
and inflammatory factors [2, 14]. We wondered whether 
endothelial cells maintain VE-cadherin protein levels during 
acute barrier rupture. TNFα-pretreated primary HUVEC and 
EA.hy926 cell monolayers were subjected to  Ca2+ switch 
assay, which provides a stimulus-independent mean of syn-
chronizing the disruption, trafficking and reformation of 
AJs [18–20]. In brief, cells were cultured in the absence 
of  Ca2+ for 20 min to disrupt cell–cell junctions, and then 
switched to normal medium to replenish normal  Ca2+ levels 
and reform contacts between cells (Fig. 3a). TEER analysis 
Fig. 2  TNFα increases VE-cadherin protein expression but not sur-
face VE-cadherin levels. a HUVECs were cultured at confluence 
for 48 h on dishes pre-coated with fibronectin, starved for 12 h and 
then stimulated with 10 ng/ml TNFα for the indicated times. Surface 
proteins were labeled with sulfo-NHS-biotin, and cells were immedi-
ately lysed. Surface-biotinylated proteins were isolated by pull-down 
assay with NeutrAvidin-agarose. Surface VE-cadherin levels were 
detected with specific antibodies from the pull-down fraction and 
compared with the expression levels from the lysates (total). ICAM-1 
was immunodetected as a control for TNFα stimulation. ERK was 
immunoblotted as a loading control. The right-hand graph shows the 
quantification of the changes in total and surface VE-cadherin expres-
sion with respect to values in unstimulated cells. Graphs show the 
mean + SEM from three independent experiments. The t test com-
pared differences between protein levels at the indicated timepoints 
of TNFα stimulation with those in unstimulated cells. *p < 0.05; 
**p < 0.01. b HUVECs were cultured as in (a) and stimulated with 
TNFα for the indicated times. Cells were fixed, permeabilized and 
stained with rabbit anti-VE-cadherin against the cytoplasmic VE-
cadherin domain, mouse anti-GM130 antibody and DAPI to label 
nuclei. Scale bar, 20  μm. Bottom graphs show the quantification of 
changes in response to TNFα of total VE-cadherin staining intensity 
(left) and VE-cadherin staining intensity in the area positive for the 
Golgi marker GM130 (right). c Changes in VE-cadherin expression 
in response to TNFα stimulation in the HUVEC derived cell line 
EA.hy926 and in HDMVEC. ERK was immunoblotted as a loading 
control
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revealed a transient rupture of the endothelial barrier and 
its rapid recovery upon  Ca2+ replenishment (Fig. 3b). This 
TEER decrease was not caused by mechanical stress induced 
by sequential buffer and medium replacements in the well 
containing the electrodes since buffer solution containing 
 Ca2+ did not induce significant changes in endothelial bar-
rier properties (Fig. 3b). TEER results obtained with ECIS 
can be mathematically modelled and separated into specific 
values, which reflect the contribution of various physiolog-
ical parameters to changes in barrier function [21].  Ca2+ 
depletion specifically decreased Rb values, which measure 
paracellular permeability, had a moderate effect on alpha 
values, which reflect cell–matrix interactions, and had 
almost no effect in cell membrane capacitance (Fig. 3c) [21]. 
ECIS modelling, therefore, suggested that the main effect 
of  Ca2+ removal is the disruption of cell–cell junctions that 
control paracellular permeability. Western blot and confo-
cal microscopy revealed that total VE-cadherin significantly 
decreased when physiological levels of  Ca2+ were replen-
ished, even though the cell monolayer recovered its barrier 
properties 60 min after replenishment (Figs. 3d–f and S3A, 
B). In contrast, the levels of PECAM-1, another junctional 
protein, remained unaltered during barrier contraction and 
reformation (Fig. 3d and S3C). These results suggested 
the involvement of other junctional components in the ini-
tial stages of barrier reformation. Indeed, tight junctions, 
detected by staining with antibodies specific for ZO-1, were 
fully reformed 60 min after  Ca2+ restoration (Fig. 3g, left). 
N-cadherin is highly expressed in human endothelial cells 
and does not localize at mature endothelial cell–cell contacts 
since it mediates heterotypic interactions between the basal 
membrane of endothelial cells and vascular smooth muscle 
cells and pericytes [17, 22, 23]. Sixty min after  Ca2+ resto-
ration, N-cadherin partially decorated endothelial cell–cell 
junctions (Fig. 3g, right), suggesting that junctional com-
plexes other than those mediated by VE-cadherin participate 
in the early recovery of cell–cell contacts after acute bar-
rier disruption. Alternative  Ca2+-switch assays, carried out 
by adding EDTA to the endothelial medium, also induced 
a decrease in VE-cadherin expression levels 60 min after 
 Ca2+ replenishment (Fig. S3A, B). In addition, proteasomal 
inhibition had little effect on total VE-cadherin decrease, 
but combinations of proteasomal and ADAM-10 inhibi-
tors prevented VE-cadherin decrease (Fig. S3C). Together, 
these results indicate that barrier repair after acute disruption 
engages VE-cadherin in a route of degradation and shed-
ding that continues even when cell–cell junctions are being 
reannealed.
To establish whether the intracellular pool of VE-cad-
herin found in TNFα-treated cells (Fig. 2b) participates 
in the regulation of surface VE-cadherin turnover during 
the  Ca2+ switch assays, we performed surface biotinylation 
experiments in combination with  Ca2+-depletion assays. 
To better detect intracellular VE-cadherin translocation 
to the cell surface, barrier recovery was prolonged up to 
90 min. First, cells were biotinylated and then subjected to 
 Ca2+ switch assays (Fig. 3h, biotinylation > CS). The reduc-
tion of surface and total levels of VE-cadherin during  Ca2+ 
replenishment was compared, revealing that surface and total 
VE-cadherin disappeared at a similar rate. Then reciprocal 
experiments were carried out in parallel: cells were sub-
jected or not to  Ca2+ switch assays and then biotinylated 
after  Ca2+ replenishment (Fig. 3h, CS > biotinylation). Total 
VE-cadherin levels decreased at a similar rate in the two 
types of experiments. However, biotinylated VE-cadherin 
levels detected during  Ca2+ replenishment when biotinyla-
tion was performed after  Ca2+ switch (CS > biotinylation) 
were significantly higher than those in cells subjected to 
biotin labeling before  Ca2+ depletion (biotinylation > CS) 
(Fig. 3h, surface, right graph, double arrowheads). This dif-
ference in VE-cadherin biotinylation during  Ca2+ replenish-
ment between the two sets of parallel experiments indicates 
that a significant proportion of surface VE-cadherin detected 
after barrier reformation was not at the plasma membrane 
before the  Ca2+ switch assay, and thus may correspond to 
the intracellular pool found in Fig. 2b. Indeed, inhibition 
of intracellular trafficking with Dynasore reduced total VE-
cadherin expression and the presence of VE-cadherin at the 
cell surface during barrier recovery (Fig. 3h, right graph). 
In conclusion, our experiments suggest that endothelial cells 
partially compensate VE-cadherin protein reduction induced 
by acute disruption by translocating the intracellular pool of 
VE-cadherin during barrier reformation.
The NF‑κB pathway mediates VE‑cadherin 
expression and maintains endothelial barrier 
integrity
VE-cadherin is fundamental to the preservation of endothe-
lial cell–cell contacts as well as to endothelial cell survival 
[5]. Reduction of VE-cadherin levels leads to massive 
collapse of the endothelial barriers in vitro [1, 13] and of 
some vascular beds in vivo [5]. Therefore, compensation 
of VE-cadherin degradation through its synthesis must be 
an essential mechanism for increasing permeability without 
compromising endothelial barrier integrity, for instance, by 
a surge in apoptosis [5]. We gained further insight into the 
TNFα-mediated increase of the intracellular VE-cadherin 
pool by investigating whether it involves transcriptional 
activation of the CDH5 gene. First, RT-qPCR analysis of a 
time course of TNFα stimulation showed an increase in the 
levels of VE-cadherin mRNA, similar to that observed at 
the protein level (Fig. 4a). In addition, the use of a panel of 
inhibitors suggested that TNFα raises VE-cadherin expres-
sion through a NF-κB-dependent pathway but not through 
a JNK-dependent pathway (Fig. 4b, c). Consistent with 
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its inhibitory effect on VE-cadherin expression, treatment 
with the NF-κB inhibitor BAY11 induced the collapse of 
the endothelial barrier as measured in TEER experiments 
and transwell permeability assays, in a similar manner to the 
barrier disruption induced upon VE-cadherin blockage with 
specific antibodies (Figs. 4d–g and S4). This collapse was 
independent of TNFα stimulation and indicated that NF-κB 
activation is critical not only for the endothelial inflamma-
tory response, but also for endothelial barrier homeostasis.
TNFα and LPS increase ETS1 expression 
in endothelial cells
The transcription factor ETS1 controls VE-cadherin expres-
sion during endothelial cell differentiation [24, 25]. In addi-
tion, ETS1 mediates proinflammatory responses in diseases 
such as rheumatoid arthritis and vascular injury [26–28]. 
This prompted us to test the effect of TNFα on ETS1 expres-
sion in human endothelial cells. TNFα induced transient 
ETS1 protein expression between 4 and 8 h post-stimula-
tion (Fig. 5a). Furthermore, LPS, an endotoxin that initiates 
the inflammatory response in vivo by inducing cytokines 
such as TNFα and IL-1β, induced ETS1 protein expression 
in HUVECs (Fig. 5b), in murine lung and kidney tissues 
(Fig. 5c) and in lung endothelial cells isolated from mice 
intraperitoneally injected with the endotoxin (Fig. 5d). Simi-
lar to VE-cadherin expression, ETS1 expression was reduced 
in the presence of BAY11, suggesting that ETS1 acts down-
stream of NF-κB (Fig. 5e). We attributed the reduced effect 
of the MG132 inhibitor to a direct effect on the degradation 
route of ETS1 itself that prevented its expression from being 
strongly inhibited.
ETS1 regulates VE‑cadherin expression 
and paracellular permeability in response to TNFα
siRNA-mediated ETS1 gene silencing reduced VE-cadherin 
levels, indicating that VE-cadherin upregulation is medi-
ated by this transcription factor (Fig. 6a). Indeed, TNFα 
induced similar kinetics of VE-cadherin and ETS1 expres-
sion increase (Fig. 6a). In contrast, ETS1 knockdown had 
no effect on ICAM-1 protein expression, a paradigmatic 
gene induced via NF-κB in response to TNFα (Fig. S5A), 
suggesting that ETS1 selectively controls VE-cadherin 
expression but no other NF-κB-regulated genes. In contrast, 
VE-cadherin knockdown had no effect on ETS1 expression 
levels (Fig. 6a). Confocal microscopy analysis confirmed 
that siETS1 reduced nuclear ETS1 and junctional VE-cad-
herin staining intensities (Fig. 6b). ETS1 nuclear transloca-
tion was coincident with the increase of VE-cadherin protein 
expression (Fig. 6a–c). It is of note that ETS1 depletion also 
reduced transient VE-cadherin accumulation in the Golgi 
area (Fig. 6d), although surface labelling with sulfo-NHS-
biotin revealed a similar decrease of total and surface VE-
cadherin levels (Fig. 6e). Unlike that of NF-κB, ETS1 inhi-
bition by siRNA-mediated knockdown had no significant 
effect on constitutive permeability in unstimulated HUVECs 
and a minor effect on TEER reduction upon TNFα stimula-
tion (Fig. 6f, left). However, mathematical modelling sug-
gested that ETS1 gene silencing specifically affects paracel-
lular permeability in response to TNFα since it exacerbated 
the decrease of Rb values (Fig. 6f, right graph), although it 
had a minor effect on cell–matrix interactions, measured by 
alpha values, and on cell membrane capacitance (Fig. S5 B). 
This also indicates that the remaining VE-cadherin expres-
sion upon ETS1 depletion, or other cadherins and junctional 
proteins unaffected by ETS1 knockdown (not shown) can 
maintain constitutive permeability in the absence of inflam-
matory challenges [2, 4, 17]. It also suggests that VE-cad-
herin is the main junctional protein orchestrating barrier 
remodeling in response to TNFα. Collectively, our results 
show that the ETS1 transcription factor is a selective regula-
tor of VE-cadherin expression and endothelial permeability 
in response to TNFα (Fig. 7).
Fig. 3  An intracellular VE-cadherin pool partially compensates 
surface VE-cadherin decrease upon acute barrier disruption a, b 
HUVECs were cultured at confluence for 48 h on dishes pre-coated 
with fibronectin, starved for 12 h and then stimulated with 10 ng/ml 
TNFα for 24  h before performing a  Ca2+ switch (CS) assay, which 
induces a transient and acute disruption of the cell monolayer in 
absence of  Ca2+ and a subsequent recovery upon  Ca2+ replenishment 
with EBM-2 endothelial culture medium. b ECIS analysis of the tran-
sient effect of  Ca2+ switch on TEER. PBS with no  Ca2+ induces a 
strong decrease in TEER, whereas PBS containing 1 mM  Ca2+ has no 
effect. c ECIS mathematical modelling of the TEER analysis in (b) 
yields three values: Rb values, which reveal changes in paracellular 
permeability (left), Alpha values, which are proportional to changes 
in cell–matrix interactions (center), and Cell membrane capacitance 
(right) [21]. d Analysis of VE-cadherin expression levels during 
the CS assay in HUVECs and EA.hy926 (EA) detected by western 
blot. e Graphs show VE-cadherin expression levels with respect to 
control cells from at least three independent experiments. *p < 0.05; 
**p < 0.01; ***p < 0.001. f VE-cadherin distribution in HUVECs 
during the CS assay. Scale bar, 20 μm. g ZO-1 and N-cadherin dis-
tribution with respect to VE-cadherin staining during the CS assay. 
Scale bar, 20  μm. h TNFα-pretreated cells were biotinylated before 
or after a CS assay. Control cells and cells recovering after 90 min of 
 Ca2+ replenishment were lysed and biotinylated proteins isolated by 
pull-down with NeutrAvidin-agarose beads. Graphs show the quan-
tification of total and surface VE-cadherin levels from three inde-
pendent experiments. *p < 0.05; **p < 0.01; ***p < 0.001. ERK was 
immunoblotted as a loading control. Double arrowhead shows differ-
ences in surface VE-cadherin during  Ca2+ replenishment when cells 
were biotinylated before and after CS, which correspond to the sur-
face localization, after barrier reformation, of VE-cadherin molecules 
that were not at the cell surface before the CS assay (right graph). 
To test whether VE-cadherin localization at the cell surface requires 
intracellular trafficking, parallel experiments of CS > biotinylation 
where performed in the presence of Dynasore during  Ca2+ replenish-
ment. See also Fig. S3
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Fig. 4  NF-κB is necessary for VE-cadherin expression and endothe-
lial barrier function. a TNFα increases VE-cadherin mRNA levels. 
RT-qPCR of VE-cadherin mRNA from HUVECs stimulated with 
TNFα for the indicated times. Graph shows the mean + SEM from 
three independent experiments performed with two pairs of oligo-
nucleotides. *p < 0.05; **p < 0.01. b The NF-κB inhibitors BAY11 
(10 μM) and MG132 (20 μM), but not the JNK inhibitor SP600125, 
abrogate the expression of VE-cadherin and ICAM-1 (positive con-
trol) but not of β-catenin, PECAM-1, tubulin and caspase-3 in 
HUVECs. Graph shows the mean + SEM from three independent 
experiments. *p < 0.05. c Decrease of VE-cadherin expression in 
the presence of the  NF-κB inhibitor BAY11 detected by immuno-
fluorescence with a specific antibody. Scale bar, 20 μm. d Effect of 
Bay11 on endothelial cell morphology detected with anti-β-catenin 
and anti-PECAM-1 antibodies. Scale bar, 20 μm. e Effect of 20 μg/
ml anti-VE-cadherin blocking antibody on endothelial adherens 
junctions detected with anti-β-catenin antibody. f The NF-κB inhibi-
tor BAY11 induces endothelial barrier collapse. HUVECs were 
cultured at confluence for 48  h on ECIS electrodes pre-coated with 
fibronectin, starved for 12 h and then stimulated or not with 10 ng/
ml TNFα in the presence or absence of 10 μm BAY11. Graphs show 
the mean + SEM from at least three independent TEER experiments. 
***p < 0.001. g  Blocking VE-cadherin with a specific antibody has 
the same effect than BAY11 on endothelial TEER levels
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Discussion
Inflammatory cytokines increase endothelial permeability 
by inducing junctional disassembly, VE-cadherin inter-
nalization and degradation, and shedding [9, 10, 29]. 
Our results suggest that VE-cadherin half-life is strongly 
reduced from 6 h to less than 3 h by long-term TNFα 
exposure and that such reduction is ameliorated by pro-
teasomal inhibition. We have also found that a combi-
nation of proteasomal and ADAM-10 inhibition clearly 
Fig. 5  ETS1 expression increases in response to TNFα and LPS 
in  vitro and in  vivo a Immunodetection of ETS1 in a time course 
of TNFα stimulation performed as in Fig.  2. Graph shows the 
mean + SEM from three independent experiments. ERK was immu-
noblotted as a loading control. b Immunodetection of ETS1 in 
HUVECs exposed or not to 1 μg/ml LPS for 17 h. Graphs show the 
mean + SEM from at least three independent experiments. c Mice 
were intraperitoneally injected with 1 mg/20 g weight LPS and eutha-
nized  18  h later. Lysates from lung and kidney were subjected to 
western blot analysis with the indicated antibodies. Graph shows the 
mean + SEM from five animals per experimental condition. ERK was 
immunoblotted as a loading control. d An endothelial cell-enriched 
fraction was isolated as described (see “Materials and methods” sec-
tion) and immunoblotted for von Willebrand factor (VWF) as an 
endothelial marker, E-cadherin as an non endothelial marker, ETS1 
and β-actin as a loading control. Graph shows the quantification of 
ETS1 expression levels in endothelial cell-enriched fractions obtained 
from four mice per experimental condition. e The NF-κB inhibi-
tor BAY11 (10  μM) reduces the expression of ETS1 in HUVECs. 
ERK was blotted as a loading control. Graphs show the mean + SEM 
from at least three independent experiments. *p < 0.05; **p < 0.01; 
***p < 0.001
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prevented VE-cadherin decrease in  Ca2+ switch assays, 
which is consistent with previous observations made in 
dermal microvascular endothelial cells [10]. These two 
degradative events may coordinate VE-cadherin decrease 
after acute barrier disruption in an inflammatory context, 
similar to the two-step mechanism of calpain-mediated 
cleavage and intracellular degradation after internalization 
recently reported for VE-cadherin [30].
Although these molecular mechanisms are critical for the 
progressive increase of endothelial paracellular permeabil-
ity, which enables a physiological inflammatory response, 
the loss of VE-cadherin at the cell surface can be devastating 
for some endothelial cell barriers. As shown here, a full VE-
cadherin inhibition, either by targeting NF-κB or with anti-
VE-cadherin-blocking antibodies, completely disrupts the 
endothelial monolayer. VE-cadherin expression transmits 
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prosurvival signaling that prevents endothelial apoptosis 
through its interaction with β-catenin [5] or by controlling 
the expression of survivin, a member of the family of inhibi-
tors of apoptosis (IAP) involved in survival and differentia-
tion that is upregulated in many cancers [31]. Hence, it is 
likely that endothelial cells, particularly those from large 
vessels such as HUVECs, establish molecular mechanisms 
to ensure enough VE-cadherin molecules at their plasma 
membrane, thus preserving barrier integrity and cell survival 
even when endothelial permeability is increased and AJs are 
transiently destabilized in an inflammatory scenario. Our 
results indicate that the progressive, TNFα-mediated VE-
cadherin degradation can be compensated by an increase of 
VE-cadherin synthesis. This compensation induces VE-cad-
herin accumulation in an intracellular compartment, which 
also partially contributes to surface VE-cadherin restoration 
during acute contraction (Fig. 7). Experiments comparing 
levels of cell surface VE-cadherin by labeling cells with bio-
tin before and after inducing acute contraction suggest an 
active vesicular trafficking of VE-cadherin from an intracel-
lular pool towards the plasma membrane during barrier ref-
ormation. This is consistent with other studies showing the 
important role for intracellular VE-cadherin trafficking from 
endosomal compartments in endothelial barrier remodeling 
in response to various stimuli [16, 32–34]. Although we 
found that VE-cadherin accumulates in a Golgi/trans-Golgi 
network compartment, the identity of the vesicular carriers 
sorting newly synthesized cadherin towards the endothelial 
plasma membrane, and their potential connection to recy-
cling endosomes remains to be investigated. It is of note that 
VE-cadherin is not essential for maintaining endothelial bar-
rier function in all tissues and type of vessels [35, 36]. This 
suggests that other endothelial junctional complexes, includ-
ing different cadherin-mediated junctions that are still poorly 
investigated, may play major roles in maintaining cell–cell 
contacts since many other cadherin superfamily members 
are expressed in human endothelial cells [22]. Our observa-
tion that complete endothelial barrier reformation occurs 
while VE-cadherin is still engaged in a degradative route, 
as well as the detection of newly formed tight junctions 
and N-cadherin-mediated junctions in early and probably 
immature cell–cell contacts, is in agreement with the exist-
ence of a wider than expected range of endothelial cell–cell 
junctional complexes that contribute to dynamically regulate 
vascular and lymphatic barrier function in different physi-
ological and pathological situations.
In addition, we have found that ETS1 selectively medi-
ates compensatory VE-cadherin synthesis, but not the 
synthesis of other TNFα-regulated genes, such as ICAM-
1. Although further transcriptomic analysis on the role 
of ETS1 in the inflammatory response of human mature 
endothelium should be carried out, our data indicate that 
ETS1 may constitute part of the transcriptional hub that 
controls compensatory responses during NF-κB-mediated 
inflammatory signaling. ETS1, one of the main transcrip-
tion factors controlling endothelial differentiation and cell 
density [24, 37], is strongly augmented by TNFα in human 
mature endothelial cells. Our results show that endothe-
lial responses to inflammatory signaling share common 
transcriptional features with endothelial cell differentia-
tion, in which the transcription of genes such as CD31 
and VE-cadherin is upregulated. Indeed, a paradigmatic 
overlapping mediated by TNFα between inflammatory and 
differentiation signaling is found in macrophage-induced 
differentiation of stem/progenitor cells into endothelial 
cells. TNFα secretion facilitates the upregulation of VE-
cadherin expression via TNFα-receptor-1 and NF-κB in 
these progenitor cells. The direct binding of the p65 subu-
nit of NF-κB to the VE-cadherin gene promoter region was 
identified, indicating that, in addition to ETS1, NF-κB also 
directly regulates CDH5 gene transcription [38]. Likewise, 
ETS1 mediates peripheral blood stem cell commitment to 
the endothelial lineage [24] and two ETS1 binding sites 
can be found in the proximal region of the CDH5 pro-
moter, necessary for VE-cadherin expression. These two 
sites bind ETS1 in vitro and are able to mediate the trans-
activation of a reporter by ETS1 [37]. The role of all these 
regulatory elements has not been investigated before in the 
context of the mature endothelial inflammatory response 
Fig. 6  ETS1 expression is required for VE-cadherin expression and 
reduces TNFα-induced paracellular permeability a siRNA-medi-
ated knockdown of ETS1 (siETS1) reduces VE-cadherin expres-
sion, whereas VE-cadherin knockdown (siVE-cadherin) does not 
affect ETS1 protein levels. TNFα induces similar kinetics of VE-
cadherin and ETS1 protein expression. Graphs show quantifications 
of VE-cadherin and ETS1 levels with respect to siControl after 8 h 
of TNFα stimulation. Mean + SEM from three independent experi-
ments. *p < 0.05; ***p < 0.001. b Confocal images showing the effect 
of TNFα stimulation and ETS1 gene silencing on VE-cadherin and 
ETS1 levels and ETS1 nuclear translocation. Double staining was 
performed with rabbit anti-ETS1 antibody and mouse anti-VE-cad-
herin antibody against the extracellular domain of the adhesion recep-
tor. Scale bar, 50 μm. c Quantification of ETS1 nuclear translocation, 
which occurs mainly at 4 h of TNFα exposure. *p < 0.05. d Effect of 
ETS1 knockdown on VE-cadherin levels in the Golgi region. Dou-
ble staining was performed with rabbit anti-VE-cadherin antibody 
against the cytoplasmic tail and mouse anti-GM130 antibody as a 
Golgi marker. Scale bar, 20  μm. Graph shows the quantification of 
VE-cadherin staining in the Golgi area performed as in Fig. 2b. ns, 
p > 0.05; *p < 0.05. e Effect of ETS1 knockdown on total and surface 
VE-cadherin levels. HUVECs were transfected with the indicated 
siRNA oligonucleotides. 72  h post-transfection, cells were labeled 
with sulfo-NHS-biotin and surface, biotinylated proteins isolated by 
pull-down with NeutrAvidin agarose as in Fig. 2a. Note that siETS1 
has no effect on the total and surface levels of PECAM-1 and on the 
loading control ERK. f Effect of ETS1 knockdown on TEER decrease 
(left graph) and Rb value decrease (right) induced by TNFα [21]. 
Graphs show the mean + SEM from three independent experiments 
measured at the indicated times of TNFα stimulation. *p < 0.05. See 
Fig. S5B
◂
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but, collectively, these previous reports and our results 
clearly indicate that the VE-cadherin promoter is regulated 
by inflammatory transcription factors, which participate in 
stem cell–endothelial differentiation and, as shown here, 
in endothelial barrier function.
The intensity, space and time of the physiological 
inflammatory response must be finely tuned to induce 
partial remodeling, but not destruction, of vessels and tis-
sues. The molecular analysis of inflammation has mainly 
focused on the proteins causing endothelial leakage. It 
is only more recently that researchers have realized the 
importance of investigating the mechanisms that counter-
act such barrier disruption and, in general, the inflamma-
tory response [39]. In addition, the inflammatory response 
can also be considered as a cellular stress response, upon 
which cells trigger homeostatic signaling. We propose 
that the observed upregulation of VE-cadherin and ETS1 
expression via NF-κB is part of the transcriptional pro-
gram that endothelial cells implement to tune vascular 
remodeling, preserve barrier integrity and recover vascular 
homeostasis in an inflammatory context.
Materials and methods
Materials
Mouse anti-VE-cadherin (610252), mouse anti-VE-
cadherin blocking antibody (610251), mouse anti-p120-
catenin (610134), mouse anti-E-cadherin (610181) and rat 
anti-mouse CD102 (553326) antibodies were purchased 
from BD. Rabbit anti-ICAM-1 (sc-7891), rabbit anti-
ERK-1/2 (sc-94), mouse anti-GM130 (sc-16268), mouse 
anti-PECAM-1 (sc-365804), mouse anti-tubulin (sc-
134241) antibodies were purchased from Santa Cruz Bio-
technology, Inc. Rabbit anti-VE-cadherin (D87F2), rabbit 
anti-JNK (9252), rabbit anti-pJNK (9251) and rabbit cas-
pase-3 (9662) antibodies were obtained from Cell Signal-
ing Technology. Rabbit anti-β-catenin (C-2206) antibody, 
mouse anti-N-cadherin (C3865) and mouse anti-β-actin 
(A-5441) antibodies were obtained from Sigma-Aldrich. 
Mouse anti-VE-cadherin (BV6) antibody was obtained 
from Enzo Life Sciences. Mouse anti-GAPDH (AB-82-45) 
Fig. 7  Endothelial cells compensate for reduction of surface VE-
cadherin half-life by expressing VE-cadherin in response to TNFα. 
Schematic model of the molecular mechanisms by which endothelial 
cells maintain enough VE-cadherin levels at the plasma membrane 
when permeability increases in response to TNFα. TNFα induces (1) 
proteasome-mediated VE-cadherin degradation and, (2) ETS1-medi-
ated VE-cadherin synthesis, which may be caused by ETS1-induced 
CDH5 gene transcription or by increasing CDH5 mRNA stability
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and mouse anti-α-catenin (EP1793Y) antibodies were pur-
chased from Abcam. Mouse anti-Plakoglobin (PG-11E4) 
and rabbit ZO-1 (40-2200) antibodies were obtained from 
Thermo-Fischer. Phalloidin-Alexa 647 (A-22287) was 
obtained from Invitrogen. Rabbit anti-von Willebrand Fac-
tor antibody (A0082) was purchased from Dako. DAPI 
(10236276001) was obtained from Roche. Goat-anti-
mouse and goat-anti-rabbit secondary antibodies were 
conjugated to Alexa Fluor-488, -555 and -647 and were 
purchased from Thermo-Fischer. Western blot secondary 
antibodies were obtained from Jackson Immunoresearch 
(donkey–anti-goat, 705-036-147 and donkey–anti-mouse, 
715-035-151) and GE Healthcare (anti-rabbit, NA934 V). 
BAY11 (B5556), MG132 (M8699), SP600125 (S5567), 
chloroquine phosphate (C6628), ammonium chloride 
(A9434), GI254023X (SML0789) and LPS (L8274) were 
purchased from Sigma-Aldrich. Lactacystin (sc-3575) was 
purchased from Santa Cruz Biotechnology, Inc. Recombi-
nant human TNFα (210-TA/CF) was obtained from R&D 
Systems.
Plasmids, siRNA, and RT‑qPCR analysis
The following siRNA oligonucleotides were obtained from 
Dharmacon: siControl1 (nontargeting control), D-001210-
01, 5′-AUG UAU UGG CCU GUA UUA GUU-3′; siControl3 
(nontargeting control) D-001810-01, 5′-UAG CGA CUA 
AAC ACA UCA A-3′ were used individually or as a pool; 
siRNA for VE-cadherin (NM_001795) 5′-GGA ACC AGA 
UGC ACA UUG A-3′. siRNA for ETS1was a SMARTpool 
(M-003887J, consisting of a pool of 4 oligonucleotides: 
5′-GAU AAA UCC UGU CAG UCU U-3′; 5′- GGA CCG UGC 
UGA CCU CAA U-3′; 5′-GGA AUU ACU CAC UGA UAA 
A-3′ and 5′-GCA UAG AGA GCU ACG AUA G-3′. siRNA 
oligonucleotides were transfected with Oligofectamine 
(Invitrogen) as previously described [1]. Oligonucleo-
tides for qPCR were purchased from Sigma-Aldrich. 1 μg 
RNA from HUVECs was subjected to reverse transcription 
with the High-Capacity RNA-cDNA kit (Applied Biosys-
tems). RT-qPCR was performed from the resulting cDNA 
in a CFX 384 thermocycler (Bio-Rad) using the SsoFast 
EvaGreen Supermix (Bio-Rad) and forward and reverse 
primers, designed with Probefinder software (Roche). 
Parallel qPCR for the housekeeping genes β-actin and 
GAPDH; F: 5′-CAG GCA CCA GGG CGTG-3´, R: 5′-GTG 
AGG ATG CCT CTC TTG CTCT-3´, and F: 5′-AGC CAC 
ATC GCT CAG ACA C-3′, R: 5′-CGC CCA ATA CGA CCA 
AAT -3′ was performed to normalize data from each point 
of stimulation. Three replicates of all the samples were 
run in parallel with non-reverse transcription controls for 
all the targets, which yielded no detectable amplification. 
VE-cadherin mRNA levels changes were analyzed with 
two pairs of primers: F: 5′-GAA CCA GAT GCA CAT TGA 
TGA-3′, R: 5′-CGA CTC ACG CTT GAC TTG AT-3′, (intron 
spanning) and F: 5′-CAA AGA CGG TCG GCT GAC AU-3′, 
R: 5′-TCT GTT CCG TTG GAC TGC CT-3′ (non-intron span-
ning) and results were pooled for quantification. Unless 
otherwise indicated, the quantification cycle (Cq) values 
fell in the 20–24 range, which denotes medium to high 
levels of these transcripts. Results were quantified and 
represented relative to the expression of unstimulated 
HUVEC  (2−ΔCq) using GenEx software, correcting for 
the efficiency of each pair of primers. The analyses were 
performed in technical triplicates. The contamination with 
genomic DNA was negligible. Subsequently, these values 
were normalized again with respect to the mean values of 
housekeeping genes used as reference. The stability of the 
candidate reference genes was probed with geNorm and 
Normfinder algorithms within GenEx, and a combination 
of the two most stable genes was chosen against which to 
normalize the results.
Cell culture and transfection
HUVECs were directly extracted from umbilical cords that 
were either generously donated by the Clínica Ruber Inter-
nacional (Madrid), thanks to Dr. Santiago Lamas (CBMSO, 
Madrid), or purchased from Lonza. Late-passage HUVECs 
lost sensitivity to inflammatory stimulation and changes in 
gene expression, so cells were maintained and used dur-
ing the first 4 passages and then discarded. EA.hy926 cells 
were a gift from C.J.S. Edgell (University of North Carolina, 
Chapel Hill, NC). Adult HDMVECs were purchased from 
Tebu-Bio. HUVECs were grown in EGM-2 medium from 
Lonza. EA.hy926 cells were grown in DMEM supplemented 
with 10% FBS. Adult HDMVEC cells were grown in CAD-
MEC medium from Tebu-Bio. All cells were incubated in 
plates precoated with 10 µg/ml human Fibronectin (Sigma-
Aldrich) at 37 °C in an atmosphere of 5% CO2/95% air.
For siRNA transfection, HUVECs were plated at subcon-
fluence (400,000 cells per 60 mm-dish) in EBM-2 medium 
(Lonza) with no antibiotics. The next day, cells were trans-
fected by mixing 4 μl of oligofectamine (Invitrogen) with 
the indicated siRNA to a final concentration of 100 nM. 24 h 
after transfection, cells were trypsinized and plated at con-
fluence onto different types of dish for parallel assays, such 
as permeability, adhesion, immunofluorescence or west-
ern blotting [14]. Experiments were performed 72 h after 
transfection.
For DNA transfection, 200,000 HUVECs were seeded 
on fibronectin-coated coverslips in 24-well dishes and were 
transfected with a mixture of 4 µg poly-ethylene-imide (PEI, 
Polysciences, Inc.) and 2 µg of plasmid DNA per coverslip. 
Medium was replaced 24 h after transfection, and experi-
ments were performed 48 h after transfection.
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Calcium switch assay
Interendothelial junctions depend on VE-cadherin homo-
philic interactions, which, in turn, rely on extracellular 
 Ca2+ availability [6]. To induce massive inter-endothelial 
junctions rupture and surface protein internalization, we 
performed transient  Ca2+ depletion assays, which con-
sisted of replacing the culture medium with phosphate 
buffer saline (which does not contain  Ca2+) for 20 min, 
followed by the addition of fresh  Ca2+ -enriched culture 
medium to induce cell–cell contact recovery. When indi-
cated, cells were incubated with 60 μM Dynasore (Cal-
biochem) during  Ca2+ replenishment. Alternatively,  Ca2+ 
depletion was induced by adding 3 mM EDTA to the cul-
ture medium.
Biotinylation assays for surface protein detection 
and western blot
We labeled cells with EZ-Link sulfo-NHS-biotin (Thermo 
Scientific) to detect surface-associated proteins [15]. In 
brief, we incubated HUVEC monolayers in 60-mm dishes 
with a solution of 0.1 mg/ml of sulfo-NHS-biotin in PBS 
supplemented with 1.5 mM  Ca2+ for 30 min. Biotinylation 
was performed at 4 °C to block membrane trafficking. 
Subsequently, we washed the excess of sulfo-NHS-biotin 
with cold PBS supplemented with  Ca2+ and incubated the 
cells with cold DMEM 10% FBS to quench the remaining 
free reagent, and then washed again. Cells were either 
directly lysed or, in the pulse-chase experiments, cultured 
at 37 °C for the indicated times and then lysed. Lysates 
were prepared by passing the cells through a 0.6-mm, 
24G needle and then centrifuged at 14,000 rpm for 5 min. 
Part of the supernatant was conserved as total lysate and 
the rest was subjected to preclearing with Sepharose 
resin, followed by pull-down with NeutrAvidin agarose 
(Thermo Scientific) to isolate biotinylated proteins. Pro-
tein extraction and immunodetection procedures were 
performed as described previously [40]. For Western blot 
analysis, equal amounts of proteins were loaded onto pol-
yacrylamide gels (8–12%) under reducing conditions and 
transferred to Immobilon-P membranes (EMD Millipore). 
After blocking with 5% nonfat dry milk or 5% BSA, the 
latter when western blotting of phosphorylated proteins 
was performed, 0.05% (vol/vol) Tween-20 in PBS, the 
membranes were incubated with the indicated antibodies, 
washed with PBS + 0.05% Tween 20, and incubated with 
the appropriate secondary antibodies coupled to HRP. 
After extensive washes, blots were developed using an 
enhanced chemiluminescence Western blotting kit (ECL; 
GE Healthcare).
Endothelial barrier function assays
Trans-endothelial electric resistance (TEER) assays with 
an electric cell-substrate impedance sensing system (ECIS 
1600R; Applied Biophysics) [41] were performed as 
described [1, 14, 18]. Unless otherwise indicated, resistance 
values at 4000 Hz were normalized to a value of 1.0 at the 
beginning of the experiments. The Rb, alpha, and membrane 
capacitance values (Cm) were modelled using the ECIS 
software (Applied Biophysics) running the experiment in 
the multi-frequency mode, which ranges between 250 and 
64000 Hz. This mathematical modelling separates TEER 
values into basolateral cell adhesion (alpha), which corre-
lates with focal adhesion formation, and paracellular bar-
rier strength (Rb) [21]. Transwell permeability assays were 
performed as described [14]. Briefly, HUVECs were plated 
at confluence onto fibronectin-coated transwells (Corning). 
After 72 h, cells were treated as indicated on the top chamber 
of the transwell. FITC-dextran (Mr 4000, Sigma-Aldrich) 
was applied on the top chamber at 0.1 mg/ml and allowed to 
equilibrate for 90 min before a sample from the medium at 
the lower chamber was collected to measure fluorescence in 
a Fusion α-FS fluorimeter.
Antibody‑mediated labeling of surface VE‑cadherin: 
confocal and time‑lapse microscopy
For confocal microscopy, cells were fixed with 4% paraform-
aldehyde for 20 min, blocked with TBS (25 mM Tris, pH 
7.4, and 150 mM NaCl) plus 10 mM Gly for 10 min, perme-
abilized for 5 min with TBS containing 0.2% Triton X-100 
at 4 °C, blocked with TBS containing 3% BSA for 30 min 
and incubated at 37 °C with primary antibodies and, after 
extensive washes, with fluorophore-conjugated secondary 
antibodies and Alexa Fluor 647-labeled phalloidin and/or 
DAPI. Surface labeling of VE-cadherin with a specific anti-
body was performed as described [16]. Confocal laser scan-
ning microscopy was performed with an LSM510 (ZEISS) 
coupled to an Axiovert 200 M microscope, as previously 
described [1]. Briefly, we used 63 ×/1.4 oil Plan-Apochromat 
and 100 ×/1.3 oil Plan-Neofluar objectives to acquire images 
of subcellular structures. Acquisition software (LSM510 
4.2) was provided by Zeiss.
Junctional VE-cadherin intensity was quantified with 
ImageJ. Briefly, an area containing the whole cell was cre-
ated and then made 10 pixels smaller to exclude the junc-
tional region. This image was then subtracted from the origi-
nal region to generate a region representing the fluorescence 
intensity at the cell periphery. The raw pixel intensity sur-
face VE-cadherin was divided by the corresponding area to 
yield a parameter that could be compared across the different 
images.
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Intraperitoneal injection of LPS
Five mice per condition were intraperitoneally injected 
with 50 μg/g LPS or saline. 17 h later, a retro-orbital injec-
tion of 150 μl 0.5% w/v Evans Blue (Merck) was per-
formed as a control of LPS effect on tissue circulation. 
30 min post-injection, mice were euthanized and 100 mg 
of lung and kidney were collected from each mouse. 
Evans blue was extracted with formamide at 55 °C for 
48 h, measured spectrophotometrically and normalized to 
the tissue weight revealing an increase of tissue edema in 
response to LPS injection (not shown). Simultaneously, 
protein concentration from tissue lysates was measured 
with BCA protein assay (ThermoFisher) and subjected 
to Western blot assays with the indicated antibodies. To 
isolate an endothelial cell-enriched fraction [42, 43], 
mouse lungs were minced and digested with 0.1% type I 
collagenase solution (Gibco) for 1 h at 37 °C. Lung tis-
sue was further disaggregated with a 19.5 G needle and 
subsequently filtered through a cell strainer. Lung cell 
suspension was then subjected to positive sorting with 
an antibody against the endothelial cell marker ICAM-2 
conjugated to magnetic Dynabeads Sheep Anti-Rat IgG 
(11035) from Thermo Fisher, for 30 min at 4 °C. After 
extensive washes, endothelial cell rich fraction was lysed 
with Laemmli sample buffer and subjected to western blot 
analysis.
Statistical analysis
Statistical significance was determined using the paired 
two-tailed Student t test in PRISM and Microsoft Excel.
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